Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-MUC1, hPAM4 Vector   (CAT#: GTVCR-WQ1400MR)

This product GTVCR-WQ1400MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting MUC1. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Humanized
RefSeq NM_001018016.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-MUC1, hPAM4 Vector (GTVCR-WQ1400MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1091MR IVTScrip™ pT7-VEE-mRNA-Anti-CD274, CX-072 Vector Vector CX-072
GTVCR-WQ1015MR IVTScrip™ pT7-VEE-mRNA-Anti-IL6, CNTO 136 Vector Vector CNTO 136
GTVCR-WQ1489MR IVTScrip™ pSP6-VEE-mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC Vector Vector IFN-alpha-REC
GTVCR-WQ2367MR IVTScrip™ pT7-VEE-mRNA-Anti-IL6R, aIL6R88 Vector Vector aIL6R88
GTVCR-WQ1162MR IVTScrip™ pT7-VEE-mRNA-Anti-Alkaline phosphatase substitute, ENB-0040 Vector Vector ENB-0040
GTVCR-WQ1276MR IVTScrip™ pT7-VEE-mRNA-Anti-CSF3R, G-CSF-Fc-PEG Vector Vector G-CSF-Fc-PEG
GTVCR-WQ831MR IVTScrip™ pT7-VEE-mRNA-Anti-GP, c13C6-FR1-N Vector Vector c13C6-FR1-N
GTVCR-WQ1576MR IVTScrip™ pT7-VEE-mRNA-Anti-PTPRC, Iomab-B Vector Vector Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW